Core Insights - BD reported a resilient business model with a 3.9% organic growth in fiscal 2025, alongside significant adjusted margin and earnings growth [2] - The company is on track to complete the combination of its Biosciences and Diagnostic Solutions business with Waters Corporation by the end of Q1 2026, aiming to enhance its position in the Med Tech industry [2] Financial Performance - Q4 2025 revenues reached $5.89 billion, marking an 8.3% increase year-over-year, with a 3.9% organic growth [4][6] - For FY 2025, total revenues were $21.84 billion, up 8.2% from FY 2024, with adjusted diluted EPS growing by 9.6% to $14.40 [6][27] - Q4 GAAP diluted EPS increased to $1.72, a 24.6% rise compared to the previous year [6][27] Segment Performance - BD Medical segment revenues grew by 11.2% to $3.16 billion, driven by strong performance in Advanced Patient Monitoring [9][32] - BD Life Sciences segment saw a modest growth of 2.1% to $1.37 billion, with Specimen Management showing solid performance [11][32] - BD Interventional segment revenues increased by 8.5% to $1.37 billion, with notable growth in Urology and Critical Care [12][32] Geographic Results - In the United States, revenues increased by 9.8% to $3.42 billion, while international revenues grew by 6.4% to $2.47 billion [5][32] - The U.S. market showed strong growth across various segments, particularly in Medication Delivery Solutions and Advanced Patient Monitoring [30][31] Future Outlook - The company provided guidance for FY 2026, expecting low single-digit revenue growth and adjusted diluted EPS in the range of $14.75 to $15.05 [13][14] - The outlook reflects various assumptions about market conditions and operational performance [13]

Core Insights - BD (Becton, Dickinson and Company) announced a transition plan for its CFO Chris DelOrefice, who will leave the company on December 5, 2025, with Vitor Roque appointed as interim CFO [1][2] - The company provided preliminary revenue results for the fourth quarter and full year of fiscal 2025, indicating strong growth despite challenges in certain segments [2][3] Transition of Leadership - Chris DelOrefice has been a key member of the Executive Leadership Team for four years, contributing to the BD 2025 strategy and portfolio transformation [2] - Vitor Roque, with two decades of experience at BD, will take over as interim CFO, ensuring a smooth transition [1][2] Preliminary Revenue Results - Fourth quarter preliminary revenue is approximately $5.9 billion, reflecting an estimated increase of 8.3% on a reported basis, 7.0% on a currency-neutral basis, and 3.9% on an organic basis [3][8] - Full year preliminary revenue is approximately $21.8 billion, representing an estimated increase of 8.2% on a reported basis, 7.7% on a currency-neutral basis, and 2.9% on an organic basis [3][8] Strategic Outlook - The company continues to navigate a dynamic macro environment, with strong growth in segments like BD Interventional, Advanced Patient Monitoring, and Medication Delivery Solutions [2] - BD plans to share more on its New BD strategy and expectations for fiscal 2026 in an upcoming earnings call [2] Financial Performance Metrics - The expected adjusted diluted earnings per share (EPS) for fiscal 2025 is projected to be at or above the midpoint of previously issued guidance [2] - The company emphasizes the use of non-GAAP financial measures to provide better insight into underlying operational performance [4][5]

Core Insights - BD has enrolled the first patient in the XTRACT™ Registry, a study aimed at evaluating the real-world performance of the Rotarex™ Catheter System for treating peripheral artery disease (PAD) [1][2][4] Company Overview - BD is a leading global medical technology company focused on improving medical discovery, diagnostics, and care delivery [6] - The company employs over 70,000 individuals and operates in nearly every country, addressing significant global health challenges [6] XTRACT™ Registry Details - The XTRACT™ Registry is a prospective, multi-center, single-arm study designed to collect data on the Rotarex™ Catheter System's effectiveness in treating PAD [1][2] - The registry aims to enroll up to 600 patients across 100 clinical sites in the U.S., with follow-up evaluations at 30 days, six months, and 12 months post-procedure [3][4] Rotarex™ Catheter System Features - The Rotarex™ Catheter System utilizes three mechanisms of action to effectively remove plaque and thrombus, functioning as both an atherectomy and thrombectomy device [4] - The device is designed to enhance patient outcomes by modifying and detaching mixed morphology lesions while actively aspirating material away [4] Market Context - PAD affects over 21 million Americans and more than 200 million people globally, with untreated cases leading to serious cardiovascular complications [5]